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lncRNA PSORS1C3 is regulated 
by glucocorticoids and fine-tunes 
OCT4 expression in non-pluripotent 
cells
Fatemeh Mirzadeh Azad1, Mahshid Malakootian2 & Seyed Javad Mowla1
OCT4 is a transcription factor known for its regulatory roles in stemness, tumorigenesis and stress 
response. Considering its versatile functions, expression of OCT4 is regulated at different levels. 
PSORS1C3, a long non-coding RNA overlapped with OCT4, has a putative association with immune 
mediated diseases; however, its exact functions remained to be elucidated. Here, we demonstrated 
that PSORS1C3 is regulated by glucocorticoids (GC), has two endogenously active promoters, promoter 
0 and 1, and two sets of transcripts, short and long variants. According to our findings, PSORS1C3 
promoters behaved differently during neural differentiation of NT2 cells and glucocorticoid receptor 
(GR) activation. In both processes the expression pattern of short variants differed from that of long 
variants and was similar to OCT4 expression. Furthermore, our data revealed that PSORS1C3’s 
promoter 0 could act as an enhancer for OCT4 in non-pluripotent cells, where its deletion caused a 
significant decrease in OCT4 expression. Meanwhile, during GR activation promoter 0 functioned as 
a negative regulator and alleviated transcription induction of OCT4 after GC treatment. Altogether, 
our work clarified the structure and regulation of PSORS1C3, explained its relation to immune-related 
disease through GR signaling and introduced it as a novel fine-tuner of OCT4 expression in non-
pluripotent cells.
OCT4, also named POU5F1, is the main regulator of pluripotency in stem cells1. It also has a part in tumorigen-
esis, cellular stress response, and hence is linked to various diseases from cancer to autoimmune disorders2–4. 
OCT4 possesses several isoforms with different functions at both protein and transcript levels, and their expres-
sions are regulated through different mechanisms and at various biological processes5,6.
One of the main stages of gene expression regulation occurs at transcription level. Using different promoters, 
enhancers or silencers, and transcription start sites, genes differentially respond to different biological signals7. 
Aside from transcription initiation, OCT4 expression is also regulated during splicing and post transcription by 
non-coding RNAs8.
Long non-coding RNAs (lncRNAs) are non-protein coding transcripts with a size of more than 200 nucleo-
tides. They are capable of regulating gene expression with different mechanisms such as acting as guiding mol-
ecules, scaffold and RNA or protein decoy or distributer. Apart from their transcripts, the genomic elements 
residing in lncRNAs locus, like their promoters, could exert regulatory roles on their neighboring or even distant 
genes9–11.
PSORS1C3, a lncRNA located in close vicinity to OCT4, was first discovered in a linkage analysis on psoria-
sis12. We have recently reported the existence of several novel exons and splice variants as well as two potential 
promoters for PSORS1C313. Aside from linkage association of PSORS1C3 to psoriasis and other immune medi-
ated diseases such as acute anterior uveitis14, recently Murphy et al. in their methylation analysis of brain samples 
from suicide committed depressed patients suggested that PSORS1C3 was related to Major Depressive Disorder15. 
However, scrutinizing the location of their proposed differentially methylated region (DMR) and comparing it 
with our previous findings13, indicated that the DMR was overlapping the promoter of POU5F1 novel variant, 
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OCT4C, and not PSORS1C3. Nevertheless, the exact molecular function of PSORS1C3 or its probable regulatory 
effect on OCT4 gene was not identified.
Here by analyzing PSORS1C3 promoter activity, we identified network of transcription factors that could 
bind to the region and tried to understand the regulation behind PSORS1C3 expression. We also knocked out 
PSORS1C3 promoter and assessed its effect on OCT4 expression.
Results
Transcription activity of PSORS1C3 locus. Reviewing ENCODE data demonstrated that the expres-
sion and chromatin modifications along PSORS1C3-OCT4 locus were different in stem and non-stem cells 
(Fig. 1A,B). As it can be observed in Fig. 1C, in A549 cells the active marks (H3K27ac, H3K4me3 and H3K4me1) 
were mostly concentrated at PSORS1C3 promoter upstream of exon 0 (hereafter promoter 0), but the transcrip-
tion activity was detected throughout the locus (including OCT4). However, the chromatin active marks as 
well as transcription in H1 hESC was restricted to OCT4 immediate promoter and proximal enhancer regions. 
Moreover a weak transcriptional activity could be observed downstream of PSORS1C3 internal promoter (here-
after promoter 1).
According to ENCODE CHIPseq data, PSORS1C3 promoter 0 could interact with 22 different transcription 
factors (TF, Fig. 1A). Enrichment analysis showed that many of these TFs are in charge of transcription initiation 
or inhibition in immune reactions, response to extracellular stimuli and cellular stress. Among different TFs, 
NR3C1 or glucocorticoid receptor (GR) showed an intense signal around PSORS1C3 promoter 0 in CHIPseq 
data.
PSORS1C3 promoter 0 was responsive to GR activation. A dual luciferase assay on cells transfected 
with reporter vector containing PSORS1C3 promoter 0 (promoter-Luc), a mutant in which the GRE upstream of 
promoter 0 was deleted (GREdel-Luc) (Fig. 2A), and mock vector indicated a dose-dependent increase in lucif-
erase activity, in HEK293T cells treated with different concentration of dexamethasone (DEX) and ethanol (used 
as DEX solvent, Fig. 2B). Dose curves fitting showed that EC50 value of DEX for inducing PSORS1C3 promoter 
0 activity, was approximately 100 nM (Fig. 2C). In order to understand how the promoter 0 would behave in 
endogenous context, we transfected A549 cells (which were positive for PSORS1C3 expression) with promoter 0 
construct and treated them with 100 nM DEX. The dual luciferase assay data revealed that DEX treatment caused 
a significant decrease (p value = 0.003) in PSORS1C3 promoter 0 activity, in cells transfected with promoter 
construct (Fig. 2D).
Figure 1. A visualization of ENCODE data on different histone modifications and transcription in PSORS1C3-
OCT4 locus. (A) Schematic view of PSORS1C3-OCT4 locus, containing novel spliced exons (filed boxes), 
regions with promoter activity (triangles) and their associated transcription factors. (B) Group of PSORS1C3 
short and long transcripts submitted to GenBank. (C) Histone modifications and transcription status of the 
locus according to ENCODE data in A549 and H1 cells.
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Dexamethasone treatment affected PSORS1C3 and OCT4 transcripts levels. In order to evaluate 
the possible effects of GR activation by dexamethasone on the expression of PSORS1C3 and its entangled gene, 
OCT4, A549 cells were treated with 100 nM dexamethasone and qRT-PCR was used to quantify the expression 
level of targeted genes. To evaluate PSORS1C3 expression in treated cells at different time points, we used a primer 
set specified to detect E0-E1 junction (PSO2, shown in Figs 1, 3) and a primer set corresponding to E1 (PSO3). 
Using the junctional primer set, we observed that one hour post-treatment the expression of PSORS1C3 E0 
containing variants (long variants) dropped significantly (p value = 0.003), while qRT-PCR using non-junctional 
primer set showed an up-regulation for PSORS1C3 short variants (p value = 0.005, Fig. 2E).
The qRT-PCR results for OCT4 isoforms demonstrated that OCT4A, OCT4B, OCT4B1 and OCT4C tran-
scripts levels elevated gradually after DEX treatment, with their peaks 2 hours after treatment, and declined then 
after (Fig. 2E). Their pattern of expression was similar to what we observed for PSORS1C3 during GR activation, 
when using the non-junctional primer set.
PSORS1C3 has two endogenously active promoters and sets of transcripts. For suppressing 
PSORS1C3, we decided to knock out its most 5′ promoter region using CRISPR/Cas9 system. After confirming 
the genomic deletion of PSORS1C3 promoter 0, using PCR and DNA sequencing, we measured the expression 
of PSORS1C3 with different sets of primers (Fig. 3A). Using PSO1 and PSO2 primer sets, our RT-PCR data 
showed that the expression of long variants were eradicated in the knocked out cells (ΔPsPr0, Fig. 3B). When 
PSO3 primer set (corresponding to E1) was used, however, a weak expression of PSORS1C3 could be detected 
(Fig. 3B). The latter finding indicated that the PSORS1C3 promoter 1 could initiate transcription at a lower level 
and generate short variants.
OCT4 variants were down-regulated in ΔPsPr0 cells. In order to assess any possible effects of 
PSORS1C3 promoter deletion on OCT4 expression, we used Western blotting and qRT-PCR to evaluate the 
expression of OCT4A protein and transcript along with three more isoforms of OCT4 namely OCT4B, OCT4B1 
and OCT4C in ΔPsPr0 cells. Our data revealed that the expression of OCT4 isoforms were extremely decreased 
Figure 2. The effect of GR activation on PSORS1C3 and OCT4 expression levels. (A) Location of GRE in 
PSORS1C3 promoter 0 cloned into PGL4.14 vector. As a control we constructed a mutant promoter in which 
GRE was deleted by SOEing PCR. (B) Dual luciferase assay showed that the GRE in PSORS1C3 promoter 
was active and the promoter showed a dose dependent response to dexamethasone treatment. (C) The curve 
fit indicated that the EC50 value for dexamethasone is 100 nM. (D) The activity of PSORS1C3 promoter 0 in 
A549 cells decreased after treatment with 100 nM dexamethasone. (E) The inhibitory effect of GR activation on 
PSORS1C3 transcription was confirmed after treating A549 cells with DEX. The expression of PSORS1C3 long 
variants dropped significantly 1 h post treatment. Different isoforms of OCT4 gene showed a progressive up 
regulation after treatment followed by gradual down regulation. The expression alterations of PSORS1C3 short 
transcripts was similar to OCT4.
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in the knocked out cells, compared to the unedited A549 cells. Our Western blotting data using polyclonal anti 
Oct3/4 antibody was also in line with the qRT-PCR results as a decrease in Oct4 protein level was observed in 
edited cells (Fig. 3C,D). Our data could imply that the deleted region might act as an enhancer for OCT4 gene. To 
confirm the expression enhancing effect of the deleted area we transfected the ΔPsPr0 cells with a promoter-less 
vector containing the deleted sequence (promoter-luc). Our qPCR data confirmed that transfecting the edited 
cells with the episomal promoter sequence could rescue the OCT4 expression 48 hour post-transfection (Fig. 3E).
GR activation in ΔPsPr0 cells caused a higher elevation in OCT4 isoform expression. We 
treated ΔPsPr0 cells with 100 nM DEX to examine whether deleting the GRE located in PSORS1C3 promoter 
upstream of E0 could affect the way OCT4 and PSORS1C3 short variants respond to GR activation. Surprisingly, 
we observed a much higher elevation in OCT4 expression level after DEX treatment in ΔPsPr0 cells, in compar-
ison to the DEX treated A549 cells (Fig. 4A). Moreover, in A549 cells the expression of OCT4 isoforms started to 
decline 4 hours after treatment, whereas the same pattern was absent in the edited cells. PSORS1C3 short variants 
exhibited the same behavior in ΔPsPr0 cells after DEX treatment (Fig. 4A).
Different behavior of PSORS1C3 variants during neural differentiation of NT2 cells. In order to 
investigate the possibility of a differential transcriptional activity of PSORS1C3 promoters 0 and 1, we evaluated 
the expression of PSORS1C3’s long and short sets of variants (using primer sets PSO4 and PSO5 respectively, 
Supplementary Table 1) as well as OCT4A during neural differentiation of NT2 cells. As it can be seen in Fig. 4B, 
PSORS1C3 short variants were expressed in undifferentiated NT2 cells, where their expression was lost during 
neural differentiation. In fact, their pattern of expression was similar to that observed for OCT4A variant. On 
the contrary, PSORS1C3 long variants were not detectable in NT2 cells, neither before nor after differentiation 
(Fig. 4B).
Figure 3. Effects of PSORS1C3 promoter knock out on OCT4 expression. (A) A schematic view of the deleted 
genomic region overlapping PSORS1C3 exon 0 and its upstream promoter using CRISPR/Cas9 system. 
The deleted region are shown by red border lines. The positioning of different sets of primers for detecting 
PSORS1C3 and gRNAs (scissors) are shown in the picture. (B) Suppression of E0 containing variants in edited 
cells (ΔPsPr0) was confirmed by RT-PCR using PSO1 and PSO2 primer sets. RT-PCR on ΔPsPr0 cells by 
PSO3 primer set could detect a weak expression for PSORS1C3 internal exons. Pictures of gels were cropped 
and juxtaposed and the full length gel pictures could be found in Supplementary Fig. 2. (C) Western blotting 
indicated the downregulation of Oct4 at protein level in ΔPsPr0 cells compared to un edited A549 cells. As 
it could be confer from the borders blot pictures were cropped and juxtaposed; Full length blots at different 
resolutions and exposures could be found in Supplementary Fig. 3. (D) Deletion of PSORS1C3 promoter 0 
resulted in a significant decrease in several OCT4 isoforms. (E) Transfecting edited cells with the episomal 
vector containing the deleted DNA segment rescued OCT4 expression 48 hour after transfection.
5Scientific RepoRts |          (2019) 9:8370  | https://doi.org/10.1038/s41598-019-44827-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
Discussion
Transcriptional regulation is one of the main mechanisms for cells to control the expression of different genes16. 
OCT4 is a POU domain-containing transcription factor that regulates stemness, proliferation, stress response and 
cell cycle. The dosage of different isoforms of OCT4 transcripts and proteins is critical for the suitable regulatory 
outcome17. Therefore, cells use several strategies to fine-tune OCT4 expression and function, according to their 
needs7,8,18.
One of OCT4 neighboring gene is a lncRNA named PSORS1C3. In a recent report, we identified several 
spliced variants for PSORS1C3, starting from its canonical first exon. By discovering a novel starting exon for 
PSORS1C3, exon 0, we also extended its 5′ boundary, and discovered several long variants of PSORS1C3. In 
addition, we showed that different regions in PSORS1C3-OCT4 locus (upstream of PSORS1C3 exon 1 and exon 
0) had the ability to initiate transcription in an episomal promoter reporter assay. However, the state of their 
endogenous activity was not clarified13.
In this study, we knocked out the most 5′ promoter (promoter 0) of PSORS1C3 to suppress its expression. 
After the deletion, a residual expression for PSORS1C3 internal exons was detected, thus PSORS1C3 pro-
moter 1 was still active in edited cells. Regarding this findings, we concluded that both putative promoters were 
endogenously active and could generate different sets of transcripts. Furthermore, according to ENCODE data 
Figure 4. Different transcriptional behavior of PSORS1C3 promoters during GR activation and neural 
differentiation of NT2 cells. (A) The expression alterations of OCT4 isoforms and PSORS1C3 variants during 
GR activation in ΔPsPr0 and A549 cells. (B) Expression pattern of OCT4A (amplified by OCT4A-RTPCR 
primers), PSORS1C3 short and long variants (amplified with PSO5 and PSO4 primers sets respectively) in 
course of neural differentiation of NT2 cells. The expression alterations of PSORS1C3 short variants in course of 
neural differentiation of NT2 cells were more similar to expression pattern of OCT4A. RT-PCR samples for each 
transcript were run on a separate gel. Gel pictures were cropped and juxtaposed and full length gel could be seen 
in Supplementary Fig. 4.
6Scientific RepoRts |          (2019) 9:8370  | https://doi.org/10.1038/s41598-019-44827-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
on chromatin accessibility and our expression analysis on edited cells, the internal promoter upstream of the 
PSORS1C3 exon 1 (promoter 1) was weaker than the LTR derived promoter upstream of exon 0.
Considering the difference in promoter’s type and their targeting transcription factors, it was expected that 
they would behave differently in diverse biological events19–22. Although CHIPseq data showed that GR had 
only one response element in OCT4-PSORS1C3 locus located upstream of PSORS1C3 promoter 0, but accord-
ing to our results OCT4 and both PSORS1C3 transcription sets were differently responsive to GR activation. 
This observation could be explain by the fact that GR can enhance or repress the expression of its target genes 
directly or through second hand mediators23,24. Moreover, GR is a multitasking TF which regulates pro and 
anti-inflammatory pathways, proliferation and cellular stress all known to contribute to molecular pathology of 
immune mediated diseases like psoriasis25–28. Considering the regulatory role of OCT4 in proliferation and stress 
response, our result on positive effect of GR on expression level of OCT4 and PSORS1C3 short variants could be 
interpreted as a new regulatory path, in line with already known role of OCT4 in proliferation and stress response 
and proposing a novel role for PSORS1C3 short transcripts in these biological pathways.
The inhibitory effect of GR on PSORS1C3 promoter 0 and the expression of long variants highlights the possi-
bility of its function as a pro-inflammatory factor. The occupancy of promoter 0 with TFs like SP1 which induces 
inflammatory signaling29 supports this idea. Our findings also indicated that the difference in expression response 
of PSORS1C3 short and long variants and the similarity of short variants behavior to OCT4 could be observed 
during neural differentiation of NT2 cells. The diversity in function of different isoforms of lncRNAs is reported 
before and is mainly due to formation of distinctive structural RNA domains in different splice variants30,31.
Knocking out PSORS1C3 promoter 0 led to a significant decrease in OCT4 isoforms expression. Therefore, 
it could be suggested that the promoter region also act as an enhancer for its neighboring gene OCT4. Several 
researches highlighted the importance of enhancer-like promoters (ePromoters) in regulating gene expres-
sion32,33. Recently, Diao et al. reported that the promoters of 17 protein-coding genes could act as an enhancer 
for OCT4 expression in hESC34. Aside from our experimental findings, mining ENCODE CHIPseq data demon-
strated that PSORS1C3 promoter 0 shared some features of ePromoters. For example, it showed high level of 
occupancy by JUN, IRF and ATF/CREB family of transcription factors which are known to be associated with 
ePromoters, and modulate transcription of targeted gene in response to cellular stress32,33. It also could recruit 
YY1 protein, a factor involved in DNA looping35.
Despite our findings on the enhancing effect of PSORS1C3 promoter 0 on OCT4 expression, we observed 
that deleting the promoter area could intensify OCT4 upregulation during GR activation, and delay the rebound 
of its expression to the normal level. This negative effect could be explained by the fact that some DNA elements 
could function as both silencer and enhancer at different cells or biological states36. Moreover, some transcription 
factors that bind to PSORS1C3 promoter like BATF37, REST38, FOSL139 and YY140 could act as negative regulators 
of transcription. Thus, although the region could not completely lie into characteristics of a silencer elements, but 
by recruiting negative regulator of transcription could modulate and fine-tune the expression of OCT4. Moreover, 
according to ENCODE data, PSORS1C3 promoter 0 was only active in non-stem cells, therefore it could be 
suggested that its fine-tuning effect on OCT4 expression is restricted to somatic cancer cell lines in which the 
expression level of OCT4 transcripts are lower than that of stem cells.
Altogether, our work showed that PSORS1C3 is regulated by GC and could modulate OCT4 expression by 
acting as an enhancer as well as by recruiting negative regulators of transcription. Of course, it is needed to be 
further clarify the exact share of PSORS1C3 transcripts and genomic elements in its regulatory functions, but it 
is safe to suggest that PSORS1C3 could act as a fine tuner for OCT4 expression in non-pluripotent cells, in which 
the level of OCT4 is needed to be kept lower than that in stem cells.
Methods
Ethical statement. This research did not involve human participants or using human samples or tissues. It 
also did not include experimenting on live animals. The in vitro experiments on commercial cell lines and stand-
ard techniques of molecular genetics was approved as a PhD thesis proposal, by Tarbiat Modares Research Ethics 
Committee as well as research ethics committee of Rajaie Cardiovascular Medical and Research Center (reference 
number: RHC.AC.IR.REC.1396.61, year of approval: 2017).
Bioinformatics analysis. We used UCSC genome browser to scan genomic area around PSORS1C3 first 
exon (coined exon 0, located at chr6:31,153,779-31,154,105(hg19)) for potential promoter activity. ENCODE41 
CHIPseq data on chromatin active marks (H3K27Ac, H3K4m1 and H3K4m3) and DNaseq was used to detect 
the active area near transcription start site. Using ENCODE CHIPseq data for different transcription factors 
(TF), a list of TFs which bind to PSORS1C3 potential promoter was extracted. The TF binding sites was assigned 
using JASPAR software42. STRING software43 was used for building protein-protein interactions network and 
enrichment analysis.
Cloning promoter constructs. After bioinformatic analysis, the potential promoter region for PSORS1C3 
(−953 to +645, promoter 0) was amplified from genomic DNA using PFU (GeneAll, Korea) and specific primers 
(Supplementary Table 1) and was named Promoter-Luc. A mutant construct named GREdel-Luc, with deletion 
in GRE (−315 to −97) was built through SOEing PCR (Supplementary Table 1). The amplified constructs was 
directly cloned into PGL4.14 (Promega, USA) up stream of fire fly luciferase. The accuracy of cloned constructs 
were confirmed by sequencing (Macrogene, Korea).
Cell culture. A549 and HEK293T cell lines were obtained from Iranian biological resource center (IBRC, 
Iran). NT2 cells were gifted by Dr. Andrews’s lab. A549 and NT2 Cells were cultured in high glucose Dulbecco’s 
Modified Eagle Medium (DMEM) and HEK293T cells were grown in DMED/F12 (Thermo Fisher Scientific, 
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USA), supplied with 10% FBS (Thermo Fisher Scientific, USA), and 1% penicillin/streptomycin (Bio Basic, 
Canada) and incubated in 37 °C with 5% humified CO2. hESC-RH5 was obtained from Royan Institute for Stem 
Cell Biology and Technology (RI-SCBT, Iran) and was cultivated as described previously44.
For investigating the effects of dexamethasone treatment on the expression of targeted genes, cells were seeded 
in 24-well plates (SPL Life Sciences, South Korea). After complete adhesion, cells were treated with the EC50 
concentration of dexamethasone and were lysed for RNA extraction at different time points.
Promoter knock out using CRISPR/Cas9 system. In order to suppress PSORS1C3 expression, we 
decided to knock out its most 5′ promoter (promoter 0) using CRISPR/Cas9 system. Four different gRNAs were 
designed (Supplementary Table 1) to target the regulatory active area upstream of E0 using http://crispr.mit.
edu/about. gRNAs where cloned into pX459 vector as described before45. gRNA containing vectors were trans-
fected into A549 cells by Lipofectamin 2000 (Thermo Fisher Scientific, USA). Selection was done by treating cells 
4 hours after transfection with Puromycin (Sigma-Aldrich, USA). Edited colonies were investigated for deletion 
by PCR using flanking primers (Edited-Test) and followed by DNA sequencing.
Promoter reporter assay and EC50 calculation. HEK293T cells were seeded in 48-well plates (SPL 
Life Sciences, South Korea) and were transfected with Promoter-Luc, GREdel-Luc and mock vector using 
Lipofectamin 2000 (Thermo Fisher Scientific, USA), according to the manufacturer’s instruction. PGL4.74 vector 
(Promega, USA) containing Renilla luciferase was co-transfected with test vectors for further normalization and 
conferring transfection efficiency. Five hours after transfection, conditioned media was replaced with dexameth-
asone (Sigma-Aldrich, USA) containing media in different concentrations. To evaluate the probable false effect 
causing by ethanol, which was used as dexamethasone solvent, the same experiment was carried out by treating 
transfected cells with ethanol (Merck, Germany) containing media. Luciferase activity in the transfected cells was 
investigated 24 h after transfection by Dual-Luciferase® Reporter Assay System (Promega, USA) following the 
manufacturer’s protocol via FB12 tube luminometer (Titertek-Berthold, Germany).
After calculating the EC50 for DEX, A549 cells were transfected with promoter-Luc vector. 4 hours after trans-
fection cells media was replaced with 100 nM DEX containing media. Luciferase activity was measured 24 hours 
post treatment, as mentioned before.
Western blotting. Harvested cells were lysed with RIPA buffer (Sigma-Aldrich, USA) according to the man-
ufacturer’s instruction. Protein concentration in lysate was qualified using Bradford assay. 30 µg of total protein 
for each sample was ran on SDS-PAGE and blotted on PVDF membrane (Sigma-Aldrich, USA) afterwards. After 
blocking with albumin, membrane was incubated with anti Oct3/4 antibody (sc-8629, Santa Cruz, USA) and anti 
β-actin antibody (ProSci, USA) overnight at 4 °C. Before visualizing the membrane with ECL kit (Lumigen, USA), 
it was incubated with HRP conjugated secondary antibody for 1 hour at RT.
Neural differentiation of NT2 cells. For inducing neural differentiation in NT2 cells we used Peter 
Andrews protocol, as described before46,47. Briefly, cells were treated with 10–5 M all-trans-retinoic acid (RA) 
(Sigma-Aldrich, USA) for up to 21 days. Then, cells were passaged and re-cultured without adding retinoic acid 
to the medium. As a control group, NT2 cells were treated with 1% DMSO which was used as RA solvent.
RNA extraction and qRTPCR. Cells were lysed for RNA extraction using TRIZOL (Thermo Fisher 
Scientific, USA) in different time points. Total RNA was extracted according to the manufacture instruction. 
1 µg of RNA was first treated with DNase I (Thermo Fisher Scientific, USA) in order to eliminate DNA contam-
ination and then was reversely transcribed using PrimeScript First Strand cDNA Synthesis Kit (TaKaRa, Japan). 
The expression of target gene was evaluated using BioFACT™ 2X Real-Time PCR Master Mix (BioFact, South 
Korea) through ABI StepOne real time PCR system (Thermo Fisher Scientific, USA). Primer sequence used for 
quantifying each target gene, could be found in Supplementary Table 1. Relative expression of target genes to beta 
2-microglubolin (b2M) was calculated according to 2−ΔΔCt method.
Statistical analysis. All statistical analysis were done using GraphPad PRISM 6 software. Student t-test was 
used for investigating the significance of observed differences in gene expression levels and relative luciferase 
activity. All tests were done in 3 biological replicates and values were reported as mean ± standard deviation. P 
values below 0.05 was considered as statistically significant.
References
 1. Atlasi, Y., Mowla, S. J., Ziaee, S. A., Gokhale, P. J. & Andrews, P. W. OCT4 spliced variants are differentially expressed in human 
pluripotent and nonpluripotent cells. Stem Cells 26(12), 3068–74 (2008).
 2. Atlasi, Y., Mowla, S. J., Ziaee, S. A. & Bahrami, A. R. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. 
Int J Cancer 120(7), 1598–602 (2007).
 3. Gao, Y. et al. The novel function of OCT4B isoform-265 in genotoxic stress. Stem Cells 30(4), 665–72 (2012).
 4. Chang, Y. T. et al. The genetic polymorphisms of POU5F1 gene are associated with psoriasis vulgaris in Chinese. J Dermatol Sci 
46(2), 153–6 (2007).
 5. Li, D. et al. OCT4B modulates OCT4A expression as ceRNA in tumor cells. Oncol Rep 33(5), 2622–30 (2015).
 6. Farashahi Yazd, E. et al. OCT4B1, a novel spliced variant of OCT4, generates a stable truncated protein with a potential role in stress 
response. Cancer Lett 309(2), 170–5 (2011).
 7. Nazarov, I. B. et al. Transcription regulation of Oct4 (Pou5F1) gene by its distal enhancer. Cell and Tissue Biology 8(1), 27–32 (2014).
 8. Hawkins, P. G. & Morris, K. V. Transcriptional regulation of Oct4 by a long non-coding RNA antisense to Oct4-pseudogene 5. 
Transcription 1(3), 165–175 (2010).
 9. Li, R., Zhu, H. & Luo, Y. Understanding the Functions of Long Non-Coding RNAs through Their Higher-Order Structures. 
International Journal of Molecular Sciences 17(5), 702 (2016).
8Scientific RepoRts |          (2019) 9:8370  | https://doi.org/10.1038/s41598-019-44827-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
 10. Marchese, F. P., Raimondi, I. & Huarte, M. The multidimensional mechanisms of long noncoding RNA function. Genome Biology 
18(1), 206 (2017).
 11. Engreitz, J. M. et al. Local regulation of gene expression by lncRNA promoters, transcription and splicing. Nature 539, 452 (2016).
 12. Holm, S. J. et al. HLA-Cw*0602 associates more strongly to psoriasis in the Swedish population than variants of the novel 6p21.3 
gene PSORS1C3. Acta Derm Venereol 85(1), 2–8 (2005).
 13. Malakootian, M. F. et al. Novel spliced variants of OCT4, OCT4C and OCT4C1, with distinct expression patterns and functions in 
pluripotent and tumor cell lines. Eur J Cell Biol 96(4), 347–355 (2017).
 14. Robinson, P. C. et al. The genetic associations of acute anterior uveitis and their overlap with the genetics of ankylosing spondylitis. 
Genes Immun 17(1), 46–51 (2016).
 15. Murphy, T. M. et al. Methylomic profiling of cortex samples from completed suicide cases implicates a role for PSORS1C3 in major 
depression and suicide. Transl Psychiatry 7(1), e989 (2017).
 16. Mercer, T. R. & Mattick, J. S. Understanding the regulatory and transcriptional complexity of the genome through structure. Genome 
Research 23(7), 1081–1088 (2013).
 17. Niwa, H., Miyazaki, J. & Smith, A. G. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of 
ES cells. Nat Genet 24(4), 372–6 (2000).
 18. Kellner, S. & Kikyo, N. Transcriptional regulation of the Oct4 gene, a master gene for pluripotency. Histol Histopathol 25(3), 405–12 
(2010).
 19. Juven-Gershon, T. & Kadonaga, J. T. Regulation of gene expression via the core promoter and the basal transcriptional machinery. 
Developmental Biology 339(2), 225–229 (2010).
 20. Zehavi, Y., Kuznetsov, O., Ovadia-Shochat, A. & Juven-Gershon, T. Core Promoter Functions in the Regulation of Gene Expression 
of Drosophila Dorsal Target Genes. The Journal of Biological Chemistry 289(17), 11993–12004 (2014).
 21. Dolfini, D., Zambelli, F., Pavesi, G. & Mantovani, R. A perspective of promoter architecture from the CCAAT box. Cell Cycle 8(24), 
4127–37 (2009).
 22. Ramji, D. P. & Foka, P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochemical Journal 365(Pt 3), 
561–575 (2002).
 23. Uhlenhaut, N. H. et al. Insights into Negative Regulation by the Glucocorticoid Receptor from Genome-wide Profiling of 
Inflammatory Cistromes. Molecular Cell 49(1), 158–171 (2013).
 24. Greulich, F., Hemmer, M. C., Rollins, D. A., Rogatsky, I. & Uhlenhaut, N. H. There goes the neighborhood: Assembly of 
transcriptional complexes during the regulation of metabolism and inflammation by the glucocorticoid receptor. Steroids 
114(Supplement C), 7–15 (2016).
 25. Desmet, S. J. & Bosscher, K. D. Glucocorticoid receptors: finding the middle ground. The Journal of Clinical Investigation 127(4), 
1136–1145 (2017).
 26. Nicolaides, N. C., Galata, Z., Kino, T., Chrousos, G. P. & Charmandari, E. The Human Glucocorticoid Receptor: Molecular Basis of 
Biologic Function. Steroids 75(1), 1 (2010).
 27. Man, X. Y. et al. Impaired nuclear translocation of glucocorticoid receptors: novel findings from psoriatic epidermal keratinocytes. 
Cell Mol Life Sci 70(12), 2205–20 (2013).
 28. Newton, R. Anti-inflammatory glucocorticoids: Changing concepts. European Journal of Pharmacology 724(Supplement C), 
231–236 (2014).
 29. Liu, Y., Liao, R., Qiang, Z. & Zhang, C. Pro-inflammatory cytokine-driven PI3K/Akt/Sp1 signalling and H&lt;sub&gt;2&lt;/sub&gt;S 
production facilitates the pathogenesis of severe acute pancreatitis. Bioscience Reports, 37(2) (2017).
 30. Ziegler, C. & Kretz, M. The More the Merrier—Complexity in Long Non-Coding RNA Loci. Frontiers in Endocrinology 8, 90 (2017).
 31. Niemczyk, M. et al. Imprinted chromatin around DIRAS3 regulates alternative splicing of GNG12-AS1, a long noncoding RNA. Am 
J Hum Genet 93(2), 224–35 (2013).
 32. Medina-Rivera, A., Santiago-Algarra, D., Puthier, D. & Spicuglia, S. Widespread Enhancer Activity from Core Promoters. Trends 
Biochem Sci 43(6), 452–468 (2018).
 33. Dao, L. T. M. et al. Genome-wide characterization of mammalian promoters with distal enhancer functions. Nature Genetics 49, 
1073 (2017).
 34. Diao, Y. et al. A tiling-deletion-based genetic screen for cis-regulatory element identification in mammalian cells. Nat Methods 
14(6), 629–635 (2017).
 35. Weintraub, A. S. et al. YY1 is a Structural Regulator of Enhancer-Promoter Loops. Cell 171(7), 1573–1588.e28 (2017).
 36. Kallunki, P., Edelman, G. M. & Jones, F. S. The neural restrictive silencer element can act as both a repressor and enhancer of L1 cell 
adhesion molecule gene expression during postnatal development. Proceedings of the National Academy of Sciences 95(6), 3233–3238 
(1998).
 37. Kurachi, M. et al. The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8(+) T cells. 
Nature immunology 15(4), 373–383 (2014).
 38. Coulson, J. M. Transcriptional Regulation: Cancer, Neurons and the REST. Current Biology 15(17), R665–R668 (2005).
 39. Galvagni, F., Orlandini, M. & Oliviero, S. Role of the AP-1 transcription factor FOSL1 in endothelial cells adhesion and migration. 
Cell Adhesion & Migration 7(5), 408–411 (2013).
 40. Galvin, K. M. & Shi, Y. Multiple mechanisms of transcriptional repression by YY1. Mol Cell Biol 17(7), 3723–32 (1997).
 41. Pazin, M. J. Using the ENCODE Resource for Functional Annotation of Genetic Variants. Cold Spring Harb Protoc 2015(6), 522–36 
(2015).
 42. Sandelin, A., Alkema, W., Engström, P., Wasserman, W. W. & Lenhard, B. JASPAR: an open-access database for eukaryotic 
transcription factor binding profiles. Nucleic Acids Research 32(Database issue), D91–D94 (2004).
 43. von Mering, C. et al. STRING: known and predicted protein-protein associations, integrated and transferred across organisms. 
Nucleic Acids Res 33(Database issue), D433–7 (2005).
 44. Baharvand, H. et al. Generation of new human embryonic stem cell lines with diploid and triploid karyotypes. Development, Growth 
& Differentiation 48(2), 117–128 (2006).
 45. Santos, D. P., Kiskinis, E., Eggan, K. & Merkle, F. T. Comprehensive Protocols for CRISPR/Cas9-based Gene Editing in Human 
Pluripotent Stem Cells. Curr Protoc Stem Cell Biol 38, 5b.6.1–5b.6.60 (2016).
 46. Malakootian, M. et al. Anti-differentiation non-coding RNA, ANCR, is differentially expressed in different types of brain tumors. 
138(2), 261–270 (2018).
 47. Andrews, P. W. Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro. Dev Biol 
103(2), 285–93 (1984).
Acknowledgements
We would like to thank the great help and support of Dr. Seyed Abolfazl Motahari for bioinformatics data mining. 
This study was supported by a research grant from Iran’s National Institute for Medical Research Development 
(NIMAD).
9Scientific RepoRts |          (2019) 9:8370  | https://doi.org/10.1038/s41598-019-44827-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
Author Contributions
F.M.A. designed and performed experiments, analyzed data and wrote the manuscript; M.M. designed 
experiment, performed the neural differentiation part and edit the manuscript; S.J.M. supervised the research, 
designed the experiments, analyzed data and edit the final draft of the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-44827-7.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
